Showing 991-1000 of 1584 results for "".
- RVL Pharmaceuticals Announces New CEO, Chief Growth Officerhttps://modernaesthetics.com/news/rvl-pharmaceuticals-announces-new-ceo-chief-growth-officer/2484615/RVL Pharmaceuticals, Inc. has appointed Lori Deo as Chief Executive Officer and Amy Shah as Chief Growth Officer, signaling a strategic leadership shift aimed at accelerating growth for its lead product, Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%. Deo, who previously se
- CollPlant Launches US Logistics Hub to Support North American Growthhttps://modernaesthetics.com/news/collplant-launches-us-logistics-hub-to-support-north-american-growth/2484120/CollPlant Biotechnologies has expanded its North American operations through a new partnership with a US-based logistics hub, the company announced. The center, expected to become operational this quarter, will support the growing distribution needs for CollPlant’s recombinant human collagen (rhC
- Allergan Aesthetics Awards $400K in Grants to Women Entrepreneurs Through the Confidence Projecthttps://modernaesthetics.com/news/allergan-aesthetics-awards-400k-in-grants-to-women-entrepreneurs-through-the-confidence-project/2484037/Allergan Aesthetics, an AbbVie company, announced the 20 recipients of this year’s Confidence Project: Empowering Women Entrepreneurs grants. Each participant completed a 12-week Boostcamp and pitched their business to a panel of aesthetic entrepreneurs and Allerga
- GLP-1 Demand Holds Steady in Aesthetic Clinics Despite Regulatory Shiftshttps://modernaesthetics.com/news/glp-1-demand-holds-steady-in-aesthetic-clinics-despite-regulatory-shifts/2483599/Despite regulatory uncertainty and reported shortages, aesthetic practices continue to experience high demand for glucagon-like peptide-1 (GLP-1) receptor agonists, according to a report released by Guidepoint Qsight on October 1, 2025.
- Study Evaluates Ready-To-Use Botox for Lateral Canthal, Glabellar Lines Treatmenthttps://modernaesthetics.com/news/study-evaluates-ready-to-use-botox-for-lateral-canthal-glabellar-lines-treatment/2483549/Newly published research in Dermatologic Surgery found liquid nivobotulinumtoxinA was effective and well-tolerated in treating moderate-to-severe lateral canthal lines (LCLs) and glabellar lines (GLs). Jean Carruthers, MD, FRCSC, FRC, co-authored the study, titled “NivobotulinumtoxinA in
- Oral GLP-1 Hits Phase 3 Trial Targets; Regulatory Submissions Cominghttps://modernaesthetics.com/news/oral-glp-1-hits-phase-3-trial-targets-regulatory-submissions-coming/2483149/Eli Lilly and Company announced positive topline results from its Phase 3 ATTAIN-2 trial, showing that its investigational oral GLP-1 receptor agonist, orforglipron, achieved significant weight loss and improved cardiometabolic outcomes in adults with obesity or overweight status and type 2 diabe
- Virtual Surgical Planning Gains Ground in Maxillofacial Procedureshttps://modernaesthetics.com/news/virtual-surgical-planning-gains-ground-in-maxillofacial-procedures/2482935/Virtual surgical planning (VSP) is becoming a mainstay in oral and maxillofacial surgery, offering improved precision, shorter operative times, and more predictable patient outcomes. Increasingly used for procedures such as genioplasty and orthognathic surgery, VSP combines digital imaging with c
- Study: Aesthetic Surgeries Rise Among GLP-1 RA Patientshttps://modernaesthetics.com/news/study-aesthetic-surgeries-rise-among-glp-1-ra-patients/2476139/Aesthetic surgery among patients with previous glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is increasing compared with postbariatric surgery patients, according to new research published in the Aesthet
- Report: GLP-1s Dethrone Skincare Shifting Medical Aesthetic Spendhttps://modernaesthetics.com/news/report-glp-1s-dethrone-skincare-shifting-medical-aesthetic-spend/2475902/Weight-loss medications continue to impact the medical aesthetics industry. GLP-1s surpassed skincare as the top consumer spend category, according to a new report from Guidepoint Qsight. Guidepoint Qsight found patients are focusing on the overall wellness journey, prioritizing bundling
- Global Botulinum Toxins Market Projected to Reach $15.7 Billion by 2030https://modernaesthetics.com/news/global-botulinum-toxins-market-projected-to-reach-157-billion-by-2030/2475785/The global market for botulinum toxin products is expected to grow from $8.9 billion in 2025 to $15.7 billion by 2030, according to new projections from MarketsandMarkets, representing a compound annual growth rate (CAGR) of 11.7%. This sustained growth is attributed to increased global de